MAR 19, 2015 06:00 AM PDT

Nobel Prize Winner presents: Clinical Studies of a Candidate Drug (OSU6162) Capable of Alleviating Dysregulation of the Dopaminergic System

Presented At Neuroscience
  • Swedish Pharmacologist, Nobel Prize Winner
      Arvid Carlsson, Swedish pharmacologist who, along with Paul Greengard and Eric Kandel, was awarded the 2000 Nobel Prize for Physiology or Medicine for his research establishing dopamine as an important neurotransmitter in the brain.

      Carlsson received a medical degree from the University of Lund in 1951 and subsequently held teaching positions there until 1959, when he became professor of pharmacology at the University of Gothenburg. When Carlsson began his pioneering studies in the 1950s, scientists thought that dopamine worked only indirectly, by causing brain cells to make another neurotransmitter, noradrenaline. Using a sensitive test that he had devised, Carlsson detected particularly high levels of the compound in areas of the brain that controlled walking and other voluntary movements. In animal experiments he showed that depletion of dopamine impairs the ability to move. When Carlsson treated dopamine-depleted animals with the amino acid l-dopa, the symptoms disappeared, and the animals moved normally again. This led to the use of l-dopa as a treatment for Parkinson disease, and it eventually became the single most important medication for the disease. Carlsson's work also contributed to an understanding of the relationship between neurotransmitters and mental states and led to the introduction of new antidepressant drugs.


    This presentation will include both preclinical and small clinical studies with details on mechanism of action, safety and efficacy of a candidate drug that has the capability of alleviating dysregulation of the dopaminergic system and also, although less clearly documented, the serotonergic system, with potential usefulness in a variety of CNS disorders.

    Show Resources
    Loading Comments...